Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
Insmed (NASDAQ:INSM) expects its drug BRINSUPRI to reach $7 billion in peak sales and anticipates becoming cash-flow positive next year. The company plans a U.S. direct-to-consumer ad campaign for BRINSUPRI and sees potential in treating bronchiectasis in asthma/COPD patients. Insmed also aims to expand ARIKAYCE's market and has multiple pipeline drugs in development, forecasting 20%+ annual revenue growth over the next decade.

